Artelo Biosciences, Inc. Board of Directors

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Mr. Gregory D. Gorgas M.B.A.

Mr. Gregory D. Gorgas M.B.A.

President, CEO, CFO, Treasurer, Secretary & Director

Dr. Andrew Yates Ph.D.

Dr. Andrew Yates Ph.D.

Senior VP & Chief Scientific Officer

Mr. Jason H. Baybutt

Mr. Jason H. Baybutt

Senior Vice President of Finance

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.